JCAR 015

Drug Profile

JCAR 015

Alternative Names: 19-28z CAR T cells; anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; anti-CD19/CD28/zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD19-specific 19-28z CAR T cells; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Jun 2017 Updated efficacy data from a phase I trial in Acute lymphoblastic leukaemia presented at the American Society for Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Pharmacodynamics and adverse events data from a phase I trial in Acute lymphoblastic leukaemia presented at the 53rd American Society for Clinical Oncology (ASCO-2017)
  • 01 Mar 2017 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) due to incidences of severe neurotoxicity and deaths due to cerebral oedema, and Juno's strategic decision
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top